news, journals and articles from all over the world.
New research in the June 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network found that when alectinib—a safe and effective small molecule kinase inhibitor used to treat some types of advanced lung cancer—was taken with a fuller breakfast, or with lunch, it resulted in significantly higher drug concentrations than when taken with a low-fat breakfast.
New research in the February 2023 issue of JNCCN—Journal of the National Comprehensive Cancer Network illustrates how the use of an algorithm to calculate a patient-reported symptom complexity score can help oncologists identify patients who are at increased risk for unplanned visits to the emergency department (ED), creating the potential for additional proactive care, and the reduction of healthcare costs.
New research in JNCCN finds that immunotherapy from immune checkpoint (PD-1) inhibitors prior to surgery was strikingly effective for patients with localized mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H) colorectal cancer (CRC).
New research in JNCCN finds that only 30% of patients with advanced neuroendocrine tumors (NETs) say their top goal for treatment is living longer. Only 51.7% of patients perceived that they had the same treatment goals as their physician.
A study in JNCCN, led by researchers at Duke University School of Medicine, found that Non-Hispanic Black patients were less likely to receive guideline-appropriate treatment for ovarian cancer compared to Non-Hispanic White patients, even after adjusting for healthcare access issues.
New research published in the October 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network confirms the safety of mRNA vaccines in people with cancer undergoing immunotherapy treatment.
New research in the September 2022 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant prognostic benefit in objectively assessing neoadjuvant chemotherapy response in borderline resectable/locally advanced pancreatic cancer patients prior to surgery.
Gerontology researchers teamed up with hematologic-oncology investigators from Brigham and Women’s Hospital and the Dana-Farber Cancer Institute to look at the association between older patients with blood cancers who were taking multiple medications and their corresponding frailty. They also created a new scale based on a list of Potentially Inappropriate Medications (PIMs) from the NCCN Guidelines® for Older Adult Oncology—called the Geriatric Oncology-Potentially Inappropriate Medications (GO-PIMs) Scale—and found it to be more effective at predicting frailty than conventional methods.
New population study in JNCCN on adjuvant hormone therapy for breast cancer finds correlation between hot flashes and poorer outcomes—in contrast to clinical trial results; likely due to patients with side-effects ending treatment early.
A new study in JNCCN finds patients with cancer who smoke are more likely to receive evidence-based cessation assistance by using the ELEVATE program, increasing the likelihood of better outcomes.
New research in JNCCN finds four out of five cancer therapies tested in Phase III trials do not achieve clinically-meaningful benefit in prolonging survival, and is the first study to quantify the number of false-positive, false-negative, and true-negative trial results.
New study in JNCCN finds that among all patients with neuroendocrine tumors (NETs), the risk of dying of cancer was higher than that of dying of other causes, but mortality varies by primary tumor site, in first population-based cohort study on cancer-specific death after a NET diagnosis.
New research in the July 2021 issue of JNCCN indicates a need to increase substance use and mental health support capabilities at cancer centers across the United States. Researchers found 85.4% of centers offered mental health services but only 45.5% had chemical dependency services.
New research in the June 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network assesses the quality of cancer care delivered through extended sites coordinated by some of the country’s largest cancer centers.
Results of new study in JNCCN from Mass General Hospital Cancer Center, Harvard Medical School, and Dana-Farber Cancer Institute underscore the need for the development and testing of nutrition and fitness interventions, as muscle quality significantly correlates with symptom burden, healthcare utilization, and survival.
New research in the February 2021 issue of JNCCN examined body mass index (BMI) data for people with HER2-positive early breast cancer, and found a 5% weight loss in patients over two years in was associated with worse outcomes. Weight gain over the same time period did not affect survival rates.
New research in the January 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds more than a third of eligible people miss timely screening tests for colorectal cancer and at least a quarter appear to miss timely screening tests for breast and cervical cancers.
New research in the November 2020 issue of JNCCN identifies metastatic pancreatic cancer patient subgroups with the highest relative cost-effectiveness from maintenance olaparib, a PARP inhibitor.
New research in the October 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds the rate of bone mineral density (BMD) testing in people with prostate cancer undergoing androgen deprivation therapy (ADT) has improved in recent years, but remains low.
New international research in the September 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds immunotherapy-related adverse events (irAEs) can impact more than one organ in a single patient. Multi-organ irAEs are more likely to happen sequentially rather than simultaneously.
New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as gene sequencing of ctDNA or “liquid biopsies.” The researchers found coverage rate rose from 0% to 38% in three years. The policies also increased in scope from 2017-2019, going from one cancer type to 12.
New research from Mass General Cancer Center, published in the June 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network, found 40.2% of hospitalized patients with advanced, incurable cancer were functionally impaired at the time of admission.
NCCN Best Practices Committee publishes peer-reviewed feature in JNCCN presenting latest insights on how to keep oncology patients and healthcare workers safe during COVID-19 pandemic. Visit NCCN.org/covid-19 for continually-updated resources for patients, providers, and care systems.
Experts from Seattle Cancer Care Alliance share lessons learned from early experiences treating people with cancer during COVID-19 outbreak via free online article in JNCCN—Journal of the National Comprehensive Cancer Network
New research from the American Cancer Society in the March 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that younger cancer survivors are more likely to experience significant financial strain for food, housing, and monthly bills after diagnosis.
Largest population-based analysis on factors that affect survival outcomes for HPV-positive oropharyngeal squamous cell carcinoma of the head and neck (SCCHN) find significant racial and socioeconomic disparities, according to new study in JNCCN-Journal of the National Comprehensive Cancer Network.
New research JNCCN—Journal of the National Comprehensive Cancer Network, using data from NHIS to examine self-reported drinking habits among people reporting a cancer diagnosis, finds 56.5% were current drinkers, 34.9% exceeded moderate drinking levels, and 21% engaged in binge drinking.
New research in the November 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network from Dana-Farber Cancer Institute examines the implications of invasive breast cancer after breast-conserving treatment for ductal carcinoma in situ (aka DCIS, a form of non-invasive breast cancer) and which factors could impact overall survival.
Study in JNCCN—Journal of the National Comprehensive Cancer Network, finds early dose reduction of adjuvant FEC-D chemotherapy negatively impacts overall survival rates for women with intermediate- or high-risk breast cancer.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu